Trial intelligence / Profile preview

Phase 3 randomized trial of asciminib versus bosutinib in CML-CP after ≥2 prior TKIs

jRCT2080223882Phase 3Completed

Sponsor

Novartis

Start

Apr 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules